Primer: Shanghai Fosun Pharmaceutical (Group) (600196 CH) - Aug 2026
Fosun Pharma is a diversified healthcare company with an integrated business model spanning pharmaceutical manufacturing, medical devices and...
93 Views
Primer: Fosun Pharma (2196 HK) - Aug 2026
Fosun Pharma is executing a strategic shift towards innovation and globalization, with revenue from innovative drugs becoming a core growth...
115 Views
Hong Kong 2025 Placements - Year so Far and Trends for Potential Primary Placements
1H25 saw a sharp turnaround in HK placements, with 36 US$100m+ deals so far. This compares to only 14 in 2022, 13 in 2023, and 15 in 2024. In this...
893 Views
Salubris (信立泰) A+H Pre-IPO: 1H26 Results Update
Salubris is seeking an A+H listing. In this note we update the company's fundamentals and business development since our last coverage.
29 Views
APAC Healthcare Weekly (Sept 13) – Hansoh, InSilico, Shionogi, Kyowa Kirin, Samsung Bio, SK Biopharm
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review. InSilico initiates rentosertib Phase 3 trial in IPF. Samsung Biologics...
96 Views